MOLA Sports的問題,透過圖書和論文來找解法和答案更準確安心。 我們找到下列包括價格和評價等資訊懶人包

臺北醫學大學 全球衛生暨衛生安全博士學位學程 陳怡樺、邱弘毅所指導 MOTSA MFUNDI PRESIDENT SEBENELE的 Prevalence and factors associated with Suicidal Behaviour in Eswatini (2021),提出MOLA Sports關鍵因素是什麼,來自於Food insecurity、being bullied、suicide behaviour、anxiety、loneliness、chronic disease、lifestyle、high blood pressure、suicidal ideation。

而第二篇論文長庚大學 機械工程學系 李德美所指導 吳振凱的 包覆水膠/微球之生物可吸收式藥物釋放球囊開發 (2020),提出因為有 化膿性細菌性關節炎、Pluronic F127、電噴霧微球、藥物釋放的重點而找出了 MOLA Sports的解答。

接下來讓我們看這些論文和書籍都說些什麼吧:

除了MOLA Sports,大家也想知道這些:

Prevalence and factors associated with Suicidal Behaviour in Eswatini

為了解決MOLA Sports的問題,作者MOTSA MFUNDI PRESIDENT SEBENELE 這樣論述:

AbstractIntroductionThe determinants of suicidal behaviour are not well understood for both adolescents and the general adult population in Eswatini. The problem of SB is a lifetime experience that can affect anyone, both young and old. Hence, the research was performed to generate evidence on the

factors associated with suicidal behavior in the aforementioned populations. This dissertation contains two studies. The first study employed a mediation approach to evaluate the roles of multiple mediators (anxiety and loneliness) in the relationship of food insecurity (FI) and being bullied (BB) o

n suicidal behavior (SB) among adolescents in schools. Additionally, it used analysis approaches to assess the combined roles of food insecurity and being bullied on SB, anxiety, and loneliness. The second study addressed whether chronic disease and lifestyle are associated with suicidal ideation (S

I) among adults in Eswatini. Moreover, the study examined the potential modification roles of socioeconomic status (SES) on the association of chronic diseases and lifestyle factors with SI.MethodsStudy hypotheses were examined through secondary analysis from the Global School-based Health Survey (G

SHS) 2012 and STEPwise Approach to NCD Risk Factor Surveillance Survey (STEPS) 2013 surveys. Both of these surveys were designed to produce nationally representative samples using stratified sampling approaches. For our analysis (study 1), we included 3,264 students aged 13-17 years, who responded t

o the questions on food insecurity, being bullied, loneliness, anxiety, and SB. Data for the primary survey were collected through self-administered questionnaires, which were executed through regular class periods. We employed bivariate and multivariate regression models to estimate factors associa

ted between FI and BB with SB, anxiety and loneliness. In addition, we used a binary mediation regression model to assess the potential mediation roles of anxiety and loneliness on the association between FI and BB with SB. The second study utilized STEPs and used a complex sampling design, where a

total of 216 primary sampling units (PSU) were selected using probability-proportionate-to-size sampling. About 20 households were systematically sampled from the PSU to form secondary sampling units. Our analysis, included 3026 adult men and women aged 18 - 69 years who gave responses to the questi

ons on suicide to ascertain the presence or absence of suicidal thoughts. Bivariate and multivariate logistic regression models were used to estimate the associated factors between chronic disease and lifestyle factors with SI.ResultsStudy 1: The results demonstrated that SB, anxiety, and loneliness

were more likely for adolescents who had combined food insecurity and being bullied; were being bullied only; were food insecure only; were physically attacked; had a fight; had no friends; were truant; used marijuana and lacked parental support (all p

包覆水膠/微球之生物可吸收式藥物釋放球囊開發

為了解決MOLA Sports的問題,作者吳振凱 這樣論述:

目錄指導教授推薦書口試委員審定書致謝 iii摘要 ivAbstract v目錄 vi圖目錄 x表目錄 xiii第一章 緒論 11-1 研究背景 11-2 生物可降解材料 31-2.1 聚乳酸聚甘醇酸共聚物(PLGA) 31-2.2 聚己內酯(PCL) 41-3 水膠(Pluronic F127) 51-4 電噴霧技術(Electrospray) 61-5 藥物介紹 71-5.1 萬古黴素(Vancomycin hydrochloride) 71-5.

2 頭孢他啶(Ceftazidime pentahydrate) 81-5.3 鹽酸利多卡因(Lidocaine hydrochloride) 81-6 研究動機與目的 10第二章 文獻回顧 112-1 化膿性細菌性關節炎(Pyogenic arthritis) 112-2 水膠攜帶藥物 122-3 電噴霧微球(Electrospray) 152-4 文獻總結 19第三章 材料設備與實驗方法 203-1 實驗流程 203-2 旋轉成型中空球囊 213-2.1

模具設計與製作 213-2.2 中空載體材料製備 223-2.3 中空載體製作 233-3 電噴霧微球 253-3.1 電噴霧設備與材料 253-3.2 電噴霧溶液調配 283-3.3 電噴霧製備微球 293-4 水膠調配 303-5 可吸收式藥物釋放球囊 313-6 表面觀察(SEM, Scanning Electron Microscope) 323-7 傅立葉轉換紅外線光譜(FTIR) 343-8 動物實驗 363-9 高效能液相層析儀(HPL

C)檢測藥量 373-9.1 高效能液相層析儀原理 373-9.2 標準溶液配製與檢量線 393-9.3 藥物濃度分析 393-9.4 高效能液相層析儀(HPLC)基本設定參數 403-10 腎功能指數(Renal function) 43第四章 結果與討論 454-1 電噴霧藥物微球 454-1.1 表面型態觀察 454-1.2 傅立葉轉換紅外線光譜(FTIR) 474-2 藥物定量分析 484-2.1 體外藥物釋放 484-3 動物實驗 51

4-3.1 體內藥物釋放情形 514-3.2 腎功能指數觀察 53第五章 結論與未來展望 555-1 結論 555-2 未來發展 57參考文獻 58圖目錄圖1- 1、PLGA化學結構圖 4圖1- 2、Pluronic ®的結構式 5圖1- 3、電噴霧液滴分裂過程 [16] 6圖1- 4、萬古黴素化學結構式 [21] 7圖1- 5、頭孢他啶化學結構式 [24] 8圖1- 6、利多卡因化學結構式 [26] 9圖2- 1、豬陰道粘膜對MTZ的藥物釋放情(MTZ溶液(□),殼聚醣/ MTZ溶液(■)和

F127 /殼聚醣/ MTZ水凝膠(•)) [14] 12圖2- 2、皮下注射rHV2溶液(□)和裝有rHV2的PF127凝膠(▴20%PF127,▪25%PF127)後血漿的rHV2濃度。 [28] 14圖2- 3、各組產出之微球(比例尺:10μm) [29] 16圖2- 4、quercetin在優化條件下製備的微球體外釋放曲線 [29] 16圖2- 5、合成PLGA多孔微粒的示意圖 [30] 17圖2- 6、不同PLGA濃度多孔微球的藥物釋放情形 [30] 18圖3- 1、實驗流程圖 20圖3- 2、兔子的股骨 21圖3- 3、模具尺寸設計圖

22圖3- 4、工廠加工流程圖 22圖3- 5、中空球囊材料(A)聚己內酯(B)六氟異丙醇 23圖3- 6、球囊製作流程圖 24圖3- 7、電噴霧設備:(A)高壓電源供應器、(B)注射幫浦、(C)10毫升針筒、(D)製具與不鏽鋼針頭 25圖3- 8、高分子聚乳酸聚甘醇共聚物(PLGA RG503) 26圖3- 9、二氯甲烷(DCM) 27圖3- 10、抗生素(A)頭孢他啶 (B)萬古黴素 (C)利多卡因 27圖3- 11、多點磁石攪拌器 28圖3- 12、實驗架設示意圖 29圖3- 14、掃描式電子顯微鏡(JEOL JSM-7500

F) 32圖3- 15、鍍金機(HITACHI,E-1010) 33圖3- 16、傅立葉轉換紅外線光譜儀 35圖3- 17、動物實驗過程 36圖3- 18、高效能液相層析儀 37圖3- 19、HPLC分析系統連接示意圖 39圖3- 20、酵素免疫生物檢測儀器(Enzyme-Linked ImmunoSorbent Assay) 44圖4- 1、微球SEM圖(x500倍率) 45圖4- 2、微球SEM圖(x1.5k倍率) 46圖4- 3、微球尺寸分布圖 46圖4- 4、FTIR光譜 47圖4- 5、Lidocaine體外釋放(A、

每日釋放;B、累積釋放) 49圖4- 6、Vancomycin體外釋放(A、每日釋放;B、累積釋放) 50圖4- 7、Ceftazidime體外釋放(A、每日釋放;B、累積釋放) 50圖4- 8、Lidocaine體內釋放 52圖4- 9、Vancomycin體內釋放 52圖4- 10、Ceftazidime體內釋放 53圖4- 11、體內血尿素氮(BUN)指數 54圖4- 12、體內血肌酸酐(Creatinine)指數 54表目錄表2- 1、不同PF127濃度下的凝膠溶解速率和rHV2釋放速率 [28] 13表2- 2、藥物聚合物溶液的成

分和電噴霧參數 [29] 15表3- 1、中空載體材料調配比例 23表3- 2、微球溶液調配比例 28表3- 3、電噴霧微球參數設定 29表3- 4、水膠配置比例 30表3- 5、球囊組別 31表3- 6、HPLC主要系統組件 38表4- 1、Lidocaine之HPLC參數設定 [34] 41表4- 2、Vancomycin hydrochloride之HPLC參數設定 [34] 41表4- 3、Ceftazidime pentahydrate之HPLC參數設定 [34] 42